×

Immudyne National Marketing Launch With GCN

MT. KISCO, N.Y., Dec. 5, 2014 (GLOBE NEWSWIRE) -- Immudyne, Inc. (OTCQB:IMMD) launches a national radio advertising campaign with Genesis Communications Network ("GCN"), to begin in December, 2014. Immudyne will market its proprietary, natural immune support products to the vast GCN audience (more than 3,500,000 daily listeners):

  • 650 AM and FM Affiliate Stations
  • Globally on Shortwave Radio
  • Live Via Telephone: (605)-562-7700
  • Internet listening options, including:
    • Live internet streams
    • On Demand
    • Program archives
    • Podcast
    • GCN iPhone App via Apple iTunes
    • GCN Android App via Google Android Market

About Immudyne

Immudyne shares trade under the ticker symbol IMMD.

Immudyne manufactures and sells proprietary, clinically researched, doctor-recommended, yeast beta-1,3/1,6-D-glucan immune support supplements, as well as topical skin care products. For the first time in its history, Immudyne has a top flight marketing team in place and is now positioned for growth.

Additional information can be found on the web at www.immudyne.com.

About GCN

For information visit www.gcnlive.com

Cautionary language regarding Forward-Looking Statements Safe Harbor Act Disclaimer: Forward-looking statements in this release are made pursuant to the Safe Harbor Provisions of the Private Securities Litigation Reform Act of 1995. Certain statements in this press release may contain words such as "anticipates," "believes," "could," "estimates," "expects," "intends," "may," "projects," "plans," "targets" and other similar language and are considered forward-looking statements. These statements are based on management's current expectations, estimates, and forecasts. These forward-looking statements are subject to important assumptions, risks and uncertainties, which are difficult to predict and therefore the actual results may be materially different from those discussed.

CONTACT: Immudyne, Inc. Mark McLaughlin +1-914-714-8901 MarkMcL@immudyne.comSource:Immudyne, Inc.